ANRS, Emerging Infectious Diseases

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection

Phase 2

Completed

Conditions: Viral Hepatitis C
HIV

Interventions: Drug: Sofosbuvir/Ledipasvir fixed dose

First Posted Date: 2014-04-29

Last Posted Date: 2017-06-29

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 68

Registration Number: NCT02125500

Locations: 🇫🇷
Centre de Méthodologie et de Gestion de Rennes, Rennes, France

Physiopathology Study of the Microbiota Biodiversity of HIV Seropositive Patients

Completed

Conditions: HIV-1 Infection

Interventions: Other: Physiopathology study

First Posted Date: 2014-04-16

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 80

Registration Number: NCT02116374

Locations: 🇫🇷
Centre Henri Mondor, Creteil, France
🇫🇷
Service de Médecine Interne et Immunologie Clinique, Le Kremlin Bicêtre, France
🇫🇷
Service de maladies Infectieuses, Marseille, France

and more 1 locations

Therapy With Asunaprevir, Daclatasvir, Ribavirin and Pegylated Interferon Alpha-2a in HCV Genotype 4-infected Patients Who Have Failed to a Previous Therapy With Peg-Interferon/Ribavirin (ANRS HC32 QUATTRO)

Phase 2

Completed

Conditions: Hepatitis C Virus Genotype 4 Infection

Interventions: Drug: Asunaprevir
Drug: Daclatasvir
Drug: Ribavirin
Drug: Pegylated Interferon alpha-2a

First Posted Date: 2014-04-08

Last Posted Date: 2017-01-24

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 60

Registration Number: NCT02107365

Locations: 🇫🇷
Hôpital Jean Verdier, Bondy, France
🇫🇷
Hôpital de Haut Lévêque, Bordeaux Pessac, France
🇫🇷
Hôpital Beaujon, Clichy, France

and more 22 locations

Evaluation of the National Treatment Program of Hepatitis C in Egypt

Withdrawn

Conditions: Chronic Hepatitis C

First Posted Date: 2014-04-02

Last Posted Date: 2014-07-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Registration Number: NCT02101177

Locations: 🇪🇬
NHTMRI, Cairo, Egypt
🇪🇬
El Fahera El Fatemia, Cairo, Egypt

Efficacy and Safety of the Combination Vitamin D With Standard of Care in Egyptian Patients With Untreated Chronic Hepatitis C

Phase 3

Withdrawn

Conditions: Chronic Hepatitis C

Interventions: Drug: Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin

First Posted Date: 2014-03-31

Last Posted Date: 2017-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Registration Number: NCT02099604

Locations: 🇪🇬
NHTMRI, Cairo, Egypt

Evaluation of Raltegravir During the Third Trimester of Pregnancy

Phase 2

Completed

Conditions: PREGNANCY
HIV-1 Infection

Interventions: Other: Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy

First Posted Date: 2014-03-31

Last Posted Date: 2017-08-22

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 83

Registration Number: NCT02099474

Locations: 🇫🇷
CHU Hôtel Dieu, Paris, France

Assessing the Severity of Metabolic-related Liver Injuries in Aging HIV-monoinfected Patients

Not Applicable

Completed

Conditions: Liver Injuries
HIV Infection

First Posted Date: 2014-03-21

Last Posted Date: 2016-07-12

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 460

Registration Number: NCT02093754

Locations: 🇩🇪
Hannover Medical School, Hannover, Germany
🇩🇪
Center for HIV and Hepato-Gastroenterology, Düsseldorf, Germany
🇧🇪
CHU Brussels, Brussels, Belgium

and more 4 locations

Systematic Empirical vs. Test-guided Anti-TB Treatment Impact in Severely Immunosuppressed HIV-infected Adults Initiating ART With CD4 Cell Counts <100/mm3

Phase 4

Completed

Conditions: HIV-1 Infection

Interventions: Device: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray
Drug: ART (Atripla, Truvada, Efavirenz, Combivir)
Drug: Rifampin, isoniazid, pyrazinamide, ethambutol

First Posted Date: 2014-02-07

Last Posted Date: 2020-10-19

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 1050

Registration Number: NCT02057796

Locations: 🇻🇳
Pham Ngoc Thach Hospital, Ho Chi Minh City, Vietnam
🇰🇭
Sihanouk Hospital Center of Hope, Phnom Penh, Cambodia
🇺🇬
ISS ImmunoSuppression Service, Mbarara, Uganda

and more 1 locations

Outcome at 5 Years of Early Treated HIV Infected Infants in the PEDIACAM Project

Active, not recruiting

Conditions: HIV

First Posted Date: 2014-01-23

Last Posted Date: 2023-08-23

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 460

Registration Number: NCT02043418

Locations: 🇨🇲
Hôpital Laquintinie, Douala, Cameroon
🇨🇲
Centre Hospitalier d'Essos, Yaounde, Cameroon
🇨🇲
Centre Mère et Enfant de la Fondation Chantal Biya, Yaounde, Cameroon

Immunogenicity and Safety of 4 Prime-boost Combinations of HIV Vaccine Candidates in Healthy Volunteers

Phase 1

Completed

Conditions: HIV Infection

Interventions: Biological: LIPO-5
Biological: MVA HIV-B (MVATG17401)

First Posted Date: 2014-01-17

Last Posted Date: 2016-06-01

Lead Sponsor: ANRS, Emerging Infectious Diseases

Target Recruit Count: 92

Registration Number: NCT02038842

Locations: 🇫🇷
Service d'Immunologie Clinique 51, avenue du Marechal de Lattre de Tassigny, Creteil, France

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy